The US drug regulator has revoked its authorization to treat with monoclonal antibodies made by Eli Lilly and Regeneron, which have been shown to be very effective in combating earlier strains of Covid-19, but have been shown not to work well against the Omicron variant.
The Food and Drug Administration announced on Monday that it was withdrawing its approval for doctors to use treatments that work by injecting patients with proteins that mimic the body’s immune response.
Dr Patricia Cavazzoni, director of the FDA’s Center for Drug Evaluation and Research, said in a statement: “As data show that these treatments are unlikely to be active against the Omicron variant, which is circulating at a very high frequency in the United States States, these treatments are not authorized for use in any state, territory, or jurisdiction in the United States at this time. “
Regeneron’s treatment helped Donald Trump recover quickly from the virus when he was infected in 2020. But federal agencies are discouraging their use as Omicron has become the dominant strain in the United States, saying it is not worth it. to expose patients to potential side effects.
However, this has sparked controversy with Ron DeSantis, the Republican governor of Florida, who accused the Biden administration of “playing games” with therapies by limiting their supply.